Table 5 Sensitivity analyses
Analysis | Cost difference vs. current practice (£) | QALY difference vs. current practice | ICER for ‘redesigned treatment pathway’ (cost per QALY gained) (£) |
|---|---|---|---|
Base-case result | −1397 | 0.01 | Dominant |
Sensitivity analysis | |||
Probability of taking warfarin with current practice (base-case 0.4) | |||
0.1 | − 3285 | −0.08 | 42,040a |
0.9 | 1522 | 0.19 | 8195 |
Reduction in probability of having moderate sensitivity in redesigned pathway (base-case 0.27) (increasing probability of having normal sensitivity) | |||
0.20 | − 1693 | 0.03 | Dominant |
0 | − 2322 | 0.06 | Dominant |
Increase in probability of having major sensitivity in redesigned pathway (base-case 0.07) | |||
0.15 | − 1081 | 0.02 | Dominant |
0.6 | 1087 | 0.04 | 30,139 |
Decrease in probability of taking warfarin if normal sensitivity in redesigned pathway (base-case 0.9) | |||
0.5 | 50 | 0.05 | 1089 |
0.1 | 1585 | 0.07 | 23,012 |